Another No For Vertex As Scotland Rejects Offer For Orkambi And Symkevi

The Scottish Medicines Consortium has issues over the price Vertex Pharmaceuticals is asking for its cystic fibrosis drugs, and like NICE in England it has rejected the products for use on the National Health Service.  

Macro photo of tooth wheel mechanism with FUNDING concept words
Scotland has recommended against funding for two CF drugs. • Source: Shutterstock

The cost of Vertex Pharmaceuticals’ cystic fibrosis drug Orkambi is under the spotlight again after the health technology appraisal body, the Scottish Medicines Consortium, recommended against the routine use of the product on the National Health Service in Scotland. Its counterpart in England, NICE, has already taken the same stance. 

The SMC announced today that it could not accept Orkambi (lumacaftor/ivacaftor) or another CF drug made by Vertex, Symkevi (tezacaftor/ivacaftor),...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe